“Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial”, J of Skin, vol. 7, no. 6, p. s257, Nov. 2023, doi: 10.25251/skin.7.supp.257.